Palvella Therapeutics
PVLA
62 hedge funds and large institutions have $36.7M invested in Palvella Therapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 9 closing their positions.
319% more call options, than puts
Call options by funds: $88K | Put options by funds: $21K
3% more capital inflows, than outflows
Capital inflows: $7.36M | Capital outflows: $7.15M
0.55% more ownership
Funds ownership: 46.89% → 47.44% (+0.55%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less funds holding
Funds holding: 65 → 62 (-3)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.15M |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.12M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$519K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$484K |
| 5 |
Millennium Management
New York
|
+$402K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.15M |
| 2 |
Great Point Partners
Greenwich,
Connecticut
|
-$2.26M |
| 3 |
Morgan Stanley
New York
|
-$943K |
| 4 |
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$121K |
| 5 |
Cerity Partners
New York
|
-$110K |
PVLA Hedge Fund Activity: Q4 2022 in Review
62 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2022, worth a combined $36.7M — down 8.5% from $40.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PVLA and 7 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 13 added.
The largest buyer was Bank of America, adding an estimated $3.15M. The largest seller was Soleus Capital Management, cutting an estimated $3.15M.
- 62 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2022, down from 65 in Q3 2022.
- Funds reported $36.7M of Palvella Therapeutics stock for Q4 2022, down 8.5% quarter-over-quarter.
- 7 funds opened new Palvella Therapeutics positions in Q4 2022 and 9 closed out, a net change of -2 holders.
- The largest Palvella Therapeutics buyer in Q4 2022 was Bank of America, an estimated $3.15M added.
- The largest Palvella Therapeutics seller in Q4 2022 was Soleus Capital Management, an estimated $3.15M sold.
Based on aggregated 13F filings for Q4 2022.